US equities
|
MU
$1,075.00
▲+2.82%
NVDA
$237.32
▼-0.80%
SNDK
$1,712.98
▲+3.16%
AMD
$644.42
▼-0.77%
SPCX
$169.47
▼-1.43%
INTC
$113.33
▲+0.74%
TSLA
$375.82
▼-1.28%
AAPL
$334.74
▲+0.33%
MU
$1,075.00
▲+2.82%
NVDA
$237.32
▼-0.80%
SNDK
$1,712.98
▲+3.16%
AMD
$644.42
▼-0.77%
SPCX
$169.47
▼-1.43%
INTC
$113.33
▲+0.74%
TSLA
$375.82
▼-1.28%
AAPL
$334.74
▲+0.33%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Sigyn Therapeutics Inc
(OP:
SIGY
)
0.0300
-0.0029 (-8.81%)
Delayed Quote
Updated: 11:58 AM EDT, Oct 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sigyn Therapeutics Inc
< Previous
1
2
3
4
Next >
Sigyn Therapeutics Inc. (SIGY) Therapeutic Candidates to Overcome Limitations in Healthcare
March 05, 2024
Via
Investor Brand Network
Sigyn Therapeutics Inc. (SIGYD) Completes Reverse Stock Split, Releases Year-End Financial Report for 2023
February 27, 2024
Via
Investor Brand Network
Sigyn Therapeutics Announces Filing of 2023 Annual Report on SEC Form 10-K
February 21, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Regulatory Compliance
BioMedNewsBreaks – Sigyn Therapeutics Inc. (SIGY, SIGYD) Announces Implementation of a 1-for-40 Reverse Split
February 02, 2024
Via
Investor Brand Network
Topics
Death
Sigyn Therapeutics Completes Reverse Stock Split
February 01, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
InvestorNewsBreaks – Sigyn Therapeutics Inc. (SIGY) to Implement 1-for-40 Reverse Split
January 30, 2024
Via
Investor Brand Network
Topics
Death
Sigyn Therapeutics Announces Reverse Stock Split
January 30, 2024
SAN DIEGO, CA - (NewMediaWire) - January 30, 2024 - Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage medical technology company, today announced that a 1-for-40...
Via
NewMediaWire
Sigyn Therapeutics Announces Reverse Stock Split
January 30, 2024
SAN DIEGO, CA - (NewMediaWire) - January 30, 2024 - Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage medical technology company, today announced that a 1-for-40...
Via
TheNewswire.com
BioMedNewsBreaks — Why Sigyn Therapeutics Inc. (SIGY) Is ‘One to Watch’
January 24, 2024
Via
Investor Brand Network
Topics
Death
Sigyn Therapeutics Inc. (SIGY) Is ‘One to Watch’
January 08, 2024
Via
Investor Brand Network
BioMedNewsBreaks – Sigyn Therapeutics Inc. (SIGY) CEO Releases Shareholder Letter Outlining Opportunities, Challenges, Processes
January 04, 2024
Via
Investor Brand Network
Topics
Death
Sigyn Therapeutics Releases Letter to Shareholders
January 04, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Sigyn Therapeutics Announces Appointment of Jerry DeCiccio as Chief Financial Officer
December 12, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Regulatory Compliance
Sigyn Therapeutics Reports Third Quarter 2023 Financial Results
November 14, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Sigyn Therapeutics Discloses PCT Patent Submission to Enhance Chemotherapy Delivery and Reduce Cancer Treatment Toxicity
October 04, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Death
Economy
Intellectual Property
Sigyn Therapeutics to Present at Today's Emerging Growth Conference and Tomorrow at the National Investment Bankers Association Conference
September 06, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Sigyn Therapeutics Reports Second Quarter 2023 Financial Results
August 14, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Sigyn Therapeutics to Present at Tomorrow's Emerging Growth Conference
August 08, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
OTCQB Venture Virtual Investor Conference: Presentations Now Available for Online Viewing
August 04, 2023
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
OTCQB Venture Virtual Investor Conference Agenda Announced for August 3rd
July 31, 2023
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Sigyn Therapeutics to Present at the OTCQB Venture Virtual Investor Conference on August 3rd
July 31, 2023
The Company invites analysts, individual and institutional investors to participate online at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Sigyn Therapeutics Discloses "DEVICES FOR ENHANCING THE ACTIVITY OF THERAPEUTIC ANTIBODIES" Patent Submission and Related ImmunePrepTM Trademark Application
May 17, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Intellectual Property
Sigyn Therapeutics Reports First Quarter 2023 Financial Results
May 16, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Sigyn Therapeutics Announces Appointment of Annette Marleau, Ph.D. as Chief Scientific Officer
April 11, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Intellectual Property
Sigyn Therapeutics Announces Filing of 2022 Annual Report on SEC Form 10-K
March 31, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Regulatory Compliance
Sigyn Therapeutics Announces Third Quarter 2022 Financial Results
November 15, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Intellectual Property
Sigyn Therapeutics Discloses Trademark Applications to Register ChemoPrepTM and ChemoPureTM for Devices to Enhance Cancer Therapy
October 13, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Intellectual Property
Sigyn Therapeutics Announces Cancer-Related Patent Submission Entitled: System and Methods to Enhance Chemotherapy Delivery and Reduce Toxicity
October 06, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Intellectual Property
Sigyn Therapeutics Strengthens Board of Directors With the Appointments of Richa Nand, Jim Dorst and Christopher Wetzel
October 04, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Intellectual Property
Sigyn Therapeutics Announces First-In-Human Clinical Strategy to Address Inflammation and Endotoxemia in End-Stage Renal Disease Patients
September 14, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Death
< Previous
1
2
3
4
Next >
